Sue Pearring
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sue Pearring has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Luke N. Rodda
Forensic Laboratory Division, Office of the Chief Medical Examiner , San Francisco, CA 94124
9 shared publications Jirair Gevorkyan
Forensic Laboratory Division, Office of the Chief Medical Examiner , 1 Newhall Street, San Francisco, CA 94124, USA
3 shared publications- Megan Farley
Office of the Chief Medical Examiner , 1 Newhall Street, San Francisco, CA 94124
3 shared publications Steven Towler
Forensic Laboratory Division, Office of the Chief Medical Examiner , 1 Newhall St., San Francisco, CA 94124
3 shared publications- Amy P. Hart
Office of the Chief Medical Examiner, San Francisco, CA
2 shared publications - Ellen Moffatt
Office of the Chief Medical Examiner, San Francisco, CA
2 shared publications
Latest Publications
- 4 June 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (6)
Characterization of postmortem γ-hydroxybutyric acid (GHB) and a novel model to discern exogenous use
Interpretation of postmortem (PM) γ-hydroxybutyric acid (GHB) remains challenging due to endogenous production and PM increases in concentration associated with decomposition. Existing interpretation guidelines primarily rely on a single criterion, such as concentration thresholds or urine-to-blood ratios. In San Francisco, routine and unbiased implementation of GHB testing across all casework generated a large dataset including 1865 GHB detections in PM blood or urine, of which 552 were paired peripheral blood and urine samples. Cases were categorized as acute exogenous use, confirmed exogenous use, or no indication of use based on toxicological and investigative findings. Peripheral blood concentrations in cases with no indication of use did not vary significantly by age, gender, race, or manner of death but were significantly higher in decomposed cases. While existing guidelines effectively identify endogenous levels, the proposed hybrid model, combining peripheral blood concentration (B) with urine-to-blood ratio (U/B), enables further classification into no exogenous use, possible exogenous use (B > 5 mg/L and U/B > –0.05 × B + 4), and acute exogenous use (B > 50 mg/L and U/B > –0.05 × B + 10). The model was evaluated and compared to existing guidelines. Internal applicability was assessed using recent casework, and external applicability was evaluated using an independent dataset from Québec, Canada. The hybrid model demonstrated improved performance, achieving substantially higher positive predictive value when compared to existing guidelines, while maintaining equal or improved performance measures across other metrics. This approach provides a conservative, evidence-based framework for distinguishing acute exogenous GHB use in PM casework.
- 4 June 2026
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 50 (6)
Characterization of postmortem γ-hydroxybutyric acid (GHB) and a novel model to discern exogenous use
Interpretation of postmortem (PM) γ-hydroxybutyric acid (GHB) remains challenging due to endogenous production and PM increases in concentration associated with decomposition. Existing interpretation guidelines primarily rely on a single criterion, such as concentration thresholds or urine-to-blood ratios. In San Francisco, routine and unbiased implementation of GHB testing across all casework generated a large dataset including 1865 GHB detections in PM blood or urine, of which 552 were paired peripheral blood and urine samples. Cases were categorized as acute exogenous use, confirmed exogenous use, or no indication of use based on toxicological and investigative findings. Peripheral blood concentrations in cases with no indication of use did not vary significantly by age, gender, race, or manner of death but were significantly higher in decomposed cases. While existing guidelines effectively identify endogenous levels, the proposed hybrid model, combining peripheral blood concentration (B) with urine-to-blood ratio (U/B), enables further classification into no exogenous use, possible exogenous use (B > 5 mg/L and U/B > –0.05 × B + 4), and acute exogenous use (B > 50 mg/L and U/B > –0.05 × B + 10). The model was evaluated and compared to existing guidelines. Internal applicability was assessed using recent casework, and external applicability was evaluated using an independent dataset from Québec, Canada. The hybrid model demonstrated improved performance, achieving substantially higher positive predictive value when compared to existing guidelines, while maintaining equal or improved performance measures across other metrics. This approach provides a conservative, evidence-based framework for distinguishing acute exogenous GHB use in PM casework.
- 24 July 2025
- Published by Wolters Kluwer Health in American Journal of Forensic Medicine & Pathology
- Vol. 46 (3) , 217-221
Bladder Wash as an Alternative Postmortem Toxicology Specimen
In postmortem forensic investigations, where the bladder is voided or dehydrated prior to autopsy, it is possible to wash the bladder with saline to collect the resulting “bladder wash” and any residual urine for toxicological analysis. Although this method is not yet commonplace or standard, a recent study has demonstrated that bladder wash is an effective alternative specimen in postmortem forensic toxicology. The current study aimed to assess forensic pathologists' opinions on the use of bladder wash samples both before and after reviewing bladder wash toxicological data. An online survey was distributed to forensic pathologists from NAME, and responses were analyzed to identify any shifts in perceptions after data presentation. The findings revealed that most forensic pathologists recognized the benefits of bladder wash collection and analysis as well as its usefulness in determining the cause and manner of death, with noticeable changes in perspective following exposure to supporting data. This study highlights the potential value of standardizing the easy and accessible collection of bladder wash for postmortem toxicological analysis, thereby providing forensic pathologists with invaluable information when other biological specimens are unavailable.
- 24 July 2025
- Published by Wolters Kluwer Health in American Journal of Forensic Medicine & Pathology
- Vol. 46 (3) , 217-221
Bladder Wash as an Alternative Postmortem Toxicology Specimen
In postmortem forensic investigations, where the bladder is voided or dehydrated prior to autopsy, it is possible to wash the bladder with saline to collect the resulting “bladder wash” and any residual urine for toxicological analysis. Although this method is not yet commonplace or standard, a recent study has demonstrated that bladder wash is an effective alternative specimen in postmortem forensic toxicology. The current study aimed to assess forensic pathologists' opinions on the use of bladder wash samples both before and after reviewing bladder wash toxicological data. An online survey was distributed to forensic pathologists from NAME, and responses were analyzed to identify any shifts in perceptions after data presentation. The findings revealed that most forensic pathologists recognized the benefits of bladder wash collection and analysis as well as its usefulness in determining the cause and manner of death, with noticeable changes in perspective following exposure to supporting data. This study highlights the potential value of standardizing the easy and accessible collection of bladder wash for postmortem toxicological analysis, thereby providing forensic pathologists with invaluable information when other biological specimens are unavailable.
- 1 April 2025
- Published by American Public Health Association in American Journal of Public Health
- Vol. 115 (4) , 555-565
The Fourth Wave of the Opioid Epidemic: Increasing Combination of Fentanyl With Stimulants
Objectives. To identify drug prevalence through the analysis of drug material and paraphernalia (DMP) collected from scenes of fentanyl-involved fatal accidental drug overdoses in San Francisco, California, throughout 2022. Methods. We conducted gas chromatography–mass spectrometry testing on 409 items of DMP (e.g., glass pipes, syringes, aluminum foil, powders) from 137 cases, and we further tested 132 DMP items using liquid chromatography–tandem mass spectrometry in context with decedent information and toxicology findings. Results. We detected fentanyl in 106 cases (77%); 35 (33%) contained fentanyl either alone or with fentanyl precursors or breakdown products. Of the 106 fentanyl-positive cases, we codetected cocaine in 29 (27%) and methamphetamine in 16 (15%). Overall, we detected methamphetamine in 58 (42%) cases (25 in isolation), cocaine in 68 (50%) cases (18 in isolation), and fentanyl analogs in 33 (24%) cases (4 in isolation). We detected 38 novel fentanyl analogs and precursors of analogs. Conclusions. We observed fentanyl use in combination with stimulants (a characteristic pattern of the opioid epidemic fourth wave). Smoking fentanyl powder using aluminum foil or snorting were the most inferred. We established polysubstance use and emerging potent novel fentanyl analogs use. ( Am J Public Health. 2025;115(4):555–565. https://doi.org/10.2105/AJPH.2024.307948 )
- 1 April 2025
- Published by American Public Health Association in American Journal of Public Health
- Vol. 115 (4) , 555-565
The Fourth Wave of the Opioid Epidemic: Increasing Combination of Fentanyl With Stimulants
Objectives. To identify drug prevalence through the analysis of drug material and paraphernalia (DMP) collected from scenes of fentanyl-involved fatal accidental drug overdoses in San Francisco, California, throughout 2022. Methods. We conducted gas chromatography–mass spectrometry testing on 409 items of DMP (e.g., glass pipes, syringes, aluminum foil, powders) from 137 cases, and we further tested 132 DMP items using liquid chromatography–tandem mass spectrometry in context with decedent information and toxicology findings. Results. We detected fentanyl in 106 cases (77%); 35 (33%) contained fentanyl either alone or with fentanyl precursors or breakdown products. Of the 106 fentanyl-positive cases, we codetected cocaine in 29 (27%) and methamphetamine in 16 (15%). Overall, we detected methamphetamine in 58 (42%) cases (25 in isolation), cocaine in 68 (50%) cases (18 in isolation), and fentanyl analogs in 33 (24%) cases (4 in isolation). We detected 38 novel fentanyl analogs and precursors of analogs. Conclusions. We observed fentanyl use in combination with stimulants (a characteristic pattern of the opioid epidemic fourth wave). Smoking fentanyl powder using aluminum foil or snorting were the most inferred. We established polysubstance use and emerging potent novel fentanyl analogs use. ( Am J Public Health. 2025;115(4):555–565. https://doi.org/10.2105/AJPH.2024.307948 )
- 13 January 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (3) , 180-190
Bladder wash: a proof of concept as an alternative specimen for postmortem toxicology
In postmortem forensic investigation cases where the bladder is voided or dehydrated prior to autopsy, it is possible to wash the bladder with saline to collect the “bladder wash” and any residual urine for toxicological analysis. While not conventional, this study aims to determine the use of bladder washes as alternative specimens in postmortem forensic toxicology. Comprehensive drug and alcohol analysis was performed on blood, urine, vitreous humor, and bladder wash samples. Control studies consisted of matched bladder wash and urine samples for comparison. Authentic applicability studies were performed on bladder wash samples in cases where only blood or no urine samples were available. Bladder wash testing via the routine urine methodology was shown to have the appropriate sensitivity and specificity to serve as an alternative specimen. Specificity of the applicability studies was further improved when comparisons were corrected by evaluating individual analytes jointly with their related parent drug or metabolites. Individual and corrected sensitivity and specificity rates of above 99% were typically observed in both comparisons against urine and blood paired samples. Following drug analysis of 31 cases in which only a bladder wash was available, 57 detections from 23 different analytes were detected that otherwise would not have been obtained. This study demonstrates that standardized collection of the easily accessible bladder wash for postmortem toxicological analysis serves forensic toxicologists and pathologists with invaluable information where urine or other biological specimens are not available.
- 13 January 2025
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (3) , 180-190
Bladder wash: a proof of concept as an alternative specimen for postmortem toxicology
In postmortem forensic investigation cases where the bladder is voided or dehydrated prior to autopsy, it is possible to wash the bladder with saline to collect the “bladder wash” and any residual urine for toxicological analysis. While not conventional, this study aims to determine the use of bladder washes as alternative specimens in postmortem forensic toxicology. Comprehensive drug and alcohol analysis was performed on blood, urine, vitreous humor, and bladder wash samples. Control studies consisted of matched bladder wash and urine samples for comparison. Authentic applicability studies were performed on bladder wash samples in cases where only blood or no urine samples were available. Bladder wash testing via the routine urine methodology was shown to have the appropriate sensitivity and specificity to serve as an alternative specimen. Specificity of the applicability studies was further improved when comparisons were corrected by evaluating individual analytes jointly with their related parent drug or metabolites. Individual and corrected sensitivity and specificity rates of above 99% were typically observed in both comparisons against urine and blood paired samples. Following drug analysis of 31 cases in which only a bladder wash was available, 57 detections from 23 different analytes were detected that otherwise would not have been obtained. This study demonstrates that standardized collection of the easily accessible bladder wash for postmortem toxicological analysis serves forensic toxicologists and pathologists with invaluable information where urine or other biological specimens are not available.
- 10 September 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (1) , 1-13
Multi-class analysis of 57 drugs quantitatively in blood and qualitatively in urine by LC–MS–MS to complement comprehensive DFC, DUID, and postmortem testing
A streamlined LC–MS–MS method utilizing protein precipitation and filtration extraction was developed to consolidate analyses for drug-facilitated crimes (DFCs), postmortem (PM) investigations, and driving under the influence of drug (DUID) testing. Fifty-seven target drug and metabolite analytes eluted in <6 minutes and were compromised of gamma-hydroxybutyric acid precursors (1), hallucinogens (3), muscle relaxants (3), anticonvulsants (7), antidepressants (20), antihistamines (5), antipsychotics (11), antihypertensives and alpha-adrenergics (3), analgesics and anesthetics (3), and miscellaneous (1) in blood (quantitatively) and urine (qualitatively). Limits of detection were set to meet the more challenging sensitivity requirements for DFC and are therefore also suitable for PM investigations and other forensic casework, including DUID. Comprehensive Academy Standards Board / American National Standards Institute (ASB/ANSI) validation was performed, and applicability studies examined 72 proficiency test blood and urine samples, along with 9206 unique blood and urine samples from 5192 authentic forensic cases that resulted in 11,961 positive analytes in samples. By expanding the analytical reach across multiple drug classes through a unified approach and screening a wider number of drugs, the technique can identify substances that might have previously evaded detection, thereby enhancing laboratory efficiency by minimizing the need for multiple tests. When combined with a recently developed in-house method, this integrated testing strategy meets the testing requirements outlined in ASB/ANSI standards and recommendations for DFC, PM, and Tier 1 DUID analyses.
- 10 September 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (1) , 1-13
Multi-class analysis of 57 drugs quantitatively in blood and qualitatively in urine by LC–MS–MS to complement comprehensive DFC, DUID, and postmortem testing
A streamlined LC–MS–MS method utilizing protein precipitation and filtration extraction was developed to consolidate analyses for drug-facilitated crimes (DFCs), postmortem (PM) investigations, and driving under the influence of drug (DUID) testing. Fifty-seven target drug and metabolite analytes eluted in <6 minutes and were compromised of gamma-hydroxybutyric acid precursors (1), hallucinogens (3), muscle relaxants (3), anticonvulsants (7), antidepressants (20), antihistamines (5), antipsychotics (11), antihypertensives and alpha-adrenergics (3), analgesics and anesthetics (3), and miscellaneous (1) in blood (quantitatively) and urine (qualitatively). Limits of detection were set to meet the more challenging sensitivity requirements for DFC and are therefore also suitable for PM investigations and other forensic casework, including DUID. Comprehensive Academy Standards Board / American National Standards Institute (ASB/ANSI) validation was performed, and applicability studies examined 72 proficiency test blood and urine samples, along with 9206 unique blood and urine samples from 5192 authentic forensic cases that resulted in 11,961 positive analytes in samples. By expanding the analytical reach across multiple drug classes through a unified approach and screening a wider number of drugs, the technique can identify substances that might have previously evaded detection, thereby enhancing laboratory efficiency by minimizing the need for multiple tests. When combined with a recently developed in-house method, this integrated testing strategy meets the testing requirements outlined in ASB/ANSI standards and recommendations for DFC, PM, and Tier 1 DUID analyses.
- 23 June 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 46 (6) , 658-669
A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC–MS-MS
Driving under the influence of drug (DUID) cases continue to challenge forensic toxicologists as both the volume and complexity of casework increases. Comprehensive DUID testing should also meet the drafted Academy Standards Board (ASB)/ American National Standard Institute (ANSI) standard and the National Safety Council’s Alcohol, Drugs and Impairment Division (NSC-ADID) recommendations. A simple method using protein precipitation followed by filtration extraction with an 8 minute run time by liquid chromatography–tandem mass spectrometry (LC–MS-MS) was developed, and a comprehensive ASB/ANSI validation was performed. Target drugs and metabolites were quantitatively assessed in blood and qualitatively assessed in urine. Included were 127 target analytes including cannabinoids (12), amphetamines (11), cocaine and metabolites (6), benzodiazepines (36), Z-drugs (5), opioids (27), anticonvulsants (3), first-generation antihistamines (6), muscle relaxants (2), dissociatives and hallucinogens (6), barbiturates (10), and miscellaneous substances (3). Limits of detection are appropriate for DUID and other forensic casework such as drug-facilitated crime (DFC) and postmortem investigations. To demonstrate applicability, 78 proficiency test blood and urine samples and 1,645 blood and urine samples from authentic cases samples demonstrated effective detection of target analytes in forensic casework. By increasing the analytical scope of multiple drug classes via a single method, this technique detects drugs that may have previously gone undetected, such as flualprazolam, etizolam, mitragynine, gamma-hydroxybutyric acid and psilocin and improves laboratory efficiency by reducing the number of tests required. The described method is, to the authors’ best knowledge, the only published single procedure to meet all drugs listed in the drafted ASB/ANSI standard and recommended Tier 1 and traditional drugs from Tier 2 for DUID screening, while also achieving many drug scope and sensitivity recommendations for DFC and postmortem testing.
- 23 June 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 46 (6) , 658-669
A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC–MS-MS
Driving under the influence of drug (DUID) cases continue to challenge forensic toxicologists as both the volume and complexity of casework increases. Comprehensive DUID testing should also meet the drafted Academy Standards Board (ASB)/ American National Standard Institute (ANSI) standard and the National Safety Council’s Alcohol, Drugs and Impairment Division (NSC-ADID) recommendations. A simple method using protein precipitation followed by filtration extraction with an 8 minute run time by liquid chromatography–tandem mass spectrometry (LC–MS-MS) was developed, and a comprehensive ASB/ANSI validation was performed. Target drugs and metabolites were quantitatively assessed in blood and qualitatively assessed in urine. Included were 127 target analytes including cannabinoids (12), amphetamines (11), cocaine and metabolites (6), benzodiazepines (36), Z-drugs (5), opioids (27), anticonvulsants (3), first-generation antihistamines (6), muscle relaxants (2), dissociatives and hallucinogens (6), barbiturates (10), and miscellaneous substances (3). Limits of detection are appropriate for DUID and other forensic casework such as drug-facilitated crime (DFC) and postmortem investigations. To demonstrate applicability, 78 proficiency test blood and urine samples and 1,645 blood and urine samples from authentic cases samples demonstrated effective detection of target analytes in forensic casework. By increasing the analytical scope of multiple drug classes via a single method, this technique detects drugs that may have previously gone undetected, such as flualprazolam, etizolam, mitragynine, gamma-hydroxybutyric acid and psilocin and improves laboratory efficiency by reducing the number of tests required. The described method is, to the authors’ best knowledge, the only published single procedure to meet all drugs listed in the drafted ASB/ANSI standard and recommended Tier 1 and traditional drugs from Tier 2 for DUID screening, while also achieving many drug scope and sensitivity recommendations for DFC and postmortem testing.
- Open Access
- 1 March 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 45 (2) , 211-214
Inferences and Legal Considerations Following a Blood Collection Tube Recall
In mid-2019, medical, forensic and legal communities were notified that a certain shipment of evacuated blood sampling tubes were recalled by the manufacturer. This recall order described that the preservative sodium fluoride (100 mg) and anticoagulant potassium oxalate (20 mg) were missing from a small batch of 10-mL evacuated tubes. This gave cause for concern for possible implications in criminal justice (e.g., in drink-driving offenses) when blood-alcohol concentrations are interpreted. In reality, the lack of an anticoagulant would have been immediately obvious during sample preparation, owing to the formation of a large clot in the tube when received. Certain impairing drugs (e.g., cocaine and 6-acetylmorphine) are unstable in blood and tend to degrade without an enzyme inhibitor, such as sodium fluoride, present. In reviewing available literature related to current practices and the stability of ethanol in stored blood samples, there does not appear to be a clear consensus regarding the amount of sodium fluoride preservative necessary, if any at all, when blood is taken from living subjects under sterile conditions for typical forensic ethanol analysis.
- 1 March 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 45 (2) , 211-214
Open AccessInferences and Legal Considerations Following a Blood Collection Tube Recall
In mid-2019, medical, forensic and legal communities were notified that a certain shipment of evacuated blood sampling tubes were recalled by the manufacturer. This recall order described that the preservative sodium fluoride (100 mg) and anticoagulant potassium oxalate (20 mg) were missing from a small batch of 10-mL evacuated tubes. This gave cause for concern for possible implications in criminal justice (e.g., in drink-driving offenses) when blood-alcohol concentrations are interpreted. In reality, the lack of an anticoagulant would have been immediately obvious during sample preparation, owing to the formation of a large clot in the tube when received. Certain impairing drugs (e.g., cocaine and 6-acetylmorphine) are unstable in blood and tend to degrade without an enzyme inhibitor, such as sodium fluoride, present. In reviewing available literature related to current practices and the stability of ethanol in stored blood samples, there does not appear to be a clear consensus regarding the amount of sodium fluoride preservative necessary, if any at all, when blood is taken from living subjects under sterile conditions for typical forensic ethanol analysis.
- 24 February 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 45 (7) , e4-e17
A Case Series of Etizolam in Opioid-Related Deaths
Etizolam is a novel psychoactive substance and novel benzodiazepine of the thienotriazolodiazepine class, which has recently seen an increasing trend in use worldwide. We report a case series of 10 decedents with etizolam and opioids in their systems. Death investigation, expanded toxicology and medical investigation information were included for contextualization of etizolam in death. Etizolam was detected and confirmed within peripheral and cardiac blood, urine, vitreous humor and, in one case, gastric fluid, by liquid chromatography–tandem mass spectrometry and liquid chromatography–quadrupole time of flight mass spectrometry methodologies. Death investigation indicated nonmedical use of most drugs. Medical investigation commonly noted pulmonary edema, cardiomegaly and cerebral swelling. The majority of the decedents appeared to be unaware of the presence of etizolam and succumbed to the mixed drug toxicity of their routine depressant and narcotic analgesic drug of abuse in combination with etizolam. Etizolam use continues to be observed and poses as a potentially lethal contribution to multiple drug toxicity, especially in the age of the opioid crisis. Assessment of analytes like etizolam requires up-to-date methodologies and vigilance in testing to better characterize the toxicology and interpret the contribution to death.
- 24 February 2021
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 45 (7) , e4-e17
A Case Series of Etizolam in Opioid-Related Deaths
Etizolam is a novel psychoactive substance and novel benzodiazepine of the thienotriazolodiazepine class, which has recently seen an increasing trend in use worldwide. We report a case series of 10 decedents with etizolam and opioids in their systems. Death investigation, expanded toxicology and medical investigation information were included for contextualization of etizolam in death. Etizolam was detected and confirmed within peripheral and cardiac blood, urine, vitreous humor and, in one case, gastric fluid, by liquid chromatography–tandem mass spectrometry and liquid chromatography–quadrupole time of flight mass spectrometry methodologies. Death investigation indicated nonmedical use of most drugs. Medical investigation commonly noted pulmonary edema, cardiomegaly and cerebral swelling. The majority of the decedents appeared to be unaware of the presence of etizolam and succumbed to the mixed drug toxicity of their routine depressant and narcotic analgesic drug of abuse in combination with etizolam. Etizolam use continues to be observed and poses as a potentially lethal contribution to multiple drug toxicity, especially in the age of the opioid crisis. Assessment of analytes like etizolam requires up-to-date methodologies and vigilance in testing to better characterize the toxicology and interpret the contribution to death.
- 6 October 2020
- Published by Wiley in Journal of Forensic Sciences
- Vol. 66 (1) , 375-382
Evaluation and applicability of Alere iCup DX 14 for rapid postmortem urine drug screening at autopsy
Performing point‐of‐care urine drug screen testing at autopsy by a forensic pathologist may provide an early indication of the presence of analytes of interest during autopsy. An evaluation for the screening of 14 classes of common drugs of abuse in postmortem urine by the point‐of‐care screening device, Alere iCup DX 14, is presented. One hundred ninety postmortem urine samples were screened with the iCup occurring at autopsy by the forensic pathologist. Positive and negative results obtained from the screening kit were evaluated against confirmatory test results obtained using routine forensic toxicology analyses that employed LC‐MS/MS and GC‐MS to detect a combination of over 85 common drugs of abuse and medications. Sensitivity for each respective iCup drug class ranged from 66% (buprenorphine) to 100% (methadone, tricyclic antidepressants). Specificity for each respective iCup drug class ranged from 89% (benzodiazepines) to 100% (amphetamines, barbiturates, buprenorphine, 3,4‐methylenedioxymethamphetamine, methadone). Positive predictive values ranged from 44% (benzodiazepines) to 100% (amphetamines, barbiturates, buprenorphine, methylenedioxymethamphetamine, methadone), while negative predictive values ranged from 96% (methamphetamine) to 100% (barbiturates, methadone, tricyclic antidepressants). A high false‐positive rate was yielded by the benzodiazepine class. The lack of fentanyl screening in the point‐of‐care device is a significant limitation considering its prolific prevalence in forensic casework. The results obtained in the study should be acknowledged when considering the use of the Alere iCup DX 14 in the context of postmortem casework to help indicate potential drug use contemporaneously with autopsy and when requiring such preliminary results prior to the release of a final forensic toxicology report.
- 6 October 2020
- Published by Wiley in Journal of Forensic Sciences
- Vol. 66 (1) , 375-382
Evaluation and applicability of Alere iCup DX 14 for rapid postmortem urine drug screening at autopsy
Performing point‐of‐care urine drug screen testing at autopsy by a forensic pathologist may provide an early indication of the presence of analytes of interest during autopsy. An evaluation for the screening of 14 classes of common drugs of abuse in postmortem urine by the point‐of‐care screening device, Alere iCup DX 14, is presented. One hundred ninety postmortem urine samples were screened with the iCup occurring at autopsy by the forensic pathologist. Positive and negative results obtained from the screening kit were evaluated against confirmatory test results obtained using routine forensic toxicology analyses that employed LC‐MS/MS and GC‐MS to detect a combination of over 85 common drugs of abuse and medications. Sensitivity for each respective iCup drug class ranged from 66% (buprenorphine) to 100% (methadone, tricyclic antidepressants). Specificity for each respective iCup drug class ranged from 89% (benzodiazepines) to 100% (amphetamines, barbiturates, buprenorphine, 3,4‐methylenedioxymethamphetamine, methadone). Positive predictive values ranged from 44% (benzodiazepines) to 100% (amphetamines, barbiturates, buprenorphine, methylenedioxymethamphetamine, methadone), while negative predictive values ranged from 96% (methamphetamine) to 100% (barbiturates, methadone, tricyclic antidepressants). A high false‐positive rate was yielded by the benzodiazepine class. The lack of fentanyl screening in the point‐of‐care device is a significant limitation considering its prolific prevalence in forensic casework. The results obtained in the study should be acknowledged when considering the use of the Alere iCup DX 14 in the context of postmortem casework to help indicate potential drug use contemporaneously with autopsy and when requiring such preliminary results prior to the release of a final forensic toxicology report.
- 4 February 2020
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 44 (5) , 422-439
Method Consolidation to Improve Scope and Efficiency in Postmortem Toxicology
Systematic toxicological approaches that employ both ideology changes and improvements in instrumentation and sample extraction allow for improved toxicology testing efficiency through lower sensitivities, higher specificity and minimized resource use. Historically, the San Francisco Office of the Chief Medical Examiner relied heavily on a gas chromatography mass spectrometry (GC–MS) testing regime, comprised of individual drug-class confirmation and quantitation assays. Traditional methods utilizing GC–MS typically require iterations of testing, exhausting sample volume, and hindering productivity and turnaround times, particularly for polypharmacy cases frequently seen in modern postmortem toxicology. The method described here consolidated the scope of seven legacy methods into a single liquid chromatography tandem mass spectrometry (LC–MS/MS) method for better sensitivity, higher throughput, minimal sample consumption for the quantitation of drugs of abuse and improved quality assurance with the incorporation of smart, automated processing. About 100 μL of blood or urine were rapidly extracted using a simple acetonitrile protein crash and subsequent in-vial filtration and injected on to an LC–MS-MS system. The developed method was fully validated to SWGTOX and international guidelines and incorporated 55 analytes along with a customized query that facilitates rapid and consistent application of acceptability criteria for data processing and review. Applicability was demonstrated with the analysis of 1,389 samples (858 blood and 531 urine) where at least 41% of positive results may have been missed due to their decreased sensitivity and 11% of results were not within the scope of the previous analytical methods estimated. On average, cases in this study would have previously required three distinct GC–MS assays, 3 mL of blood, and upwards of 30 h of active staff time. The described LC–MS-MS analytical approach has mitigated the need to perform multiple assays, utilized only 0.1 mL of sample, significantly reduced analyst work time, incorporated 10 additional analytes and allowed for a more comprehensive testing regime to better inform cause of death determinations.
- 4 February 2020
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 44 (5) , 422-439
Method Consolidation to Improve Scope and Efficiency in Postmortem Toxicology
Systematic toxicological approaches that employ both ideology changes and improvements in instrumentation and sample extraction allow for improved toxicology testing efficiency through lower sensitivities, higher specificity and minimized resource use. Historically, the San Francisco Office of the Chief Medical Examiner relied heavily on a gas chromatography mass spectrometry (GC–MS) testing regime, comprised of individual drug-class confirmation and quantitation assays. Traditional methods utilizing GC–MS typically require iterations of testing, exhausting sample volume, and hindering productivity and turnaround times, particularly for polypharmacy cases frequently seen in modern postmortem toxicology. The method described here consolidated the scope of seven legacy methods into a single liquid chromatography tandem mass spectrometry (LC–MS/MS) method for better sensitivity, higher throughput, minimal sample consumption for the quantitation of drugs of abuse and improved quality assurance with the incorporation of smart, automated processing. About 100 μL of blood or urine were rapidly extracted using a simple acetonitrile protein crash and subsequent in-vial filtration and injected on to an LC–MS-MS system. The developed method was fully validated to SWGTOX and international guidelines and incorporated 55 analytes along with a customized query that facilitates rapid and consistent application of acceptability criteria for data processing and review. Applicability was demonstrated with the analysis of 1,389 samples (858 blood and 531 urine) where at least 41% of positive results may have been missed due to their decreased sensitivity and 11% of results were not within the scope of the previous analytical methods estimated. On average, cases in this study would have previously required three distinct GC–MS assays, 3 mL of blood, and upwards of 30 h of active staff time. The described LC–MS-MS analytical approach has mitigated the need to perform multiple assays, utilized only 0.1 mL of sample, significantly reduced analyst work time, incorporated 10 additional analytes and allowed for a more comprehensive testing regime to better inform cause of death determinations.